Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Activin receptor-like kinase 1 is associated with immune cell infiltration and regulates CLEC14A transcription in cancer.

Bocci M, Sjölund J, Kurzejamska E, Lindgren D, Marzouka NA, Bartoschek M, Höglund M, Pietras K.

Angiogenesis. 2019 Feb;22(1):117-131. doi: 10.1007/s10456-018-9642-5. Epub 2018 Aug 21.

PMID:
30132150
2.

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A.

Clin Cancer Res. 2018 Dec 15;24(24):6185-6194. doi: 10.1158/1078-0432.CCR-18-0426. Epub 2018 Aug 10.

PMID:
30097433
3.

Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.

Sjödahl G, Eriksson P, Lövgren K, Marzouka NA, Bernardo C, Nordentoft I, Dyrskjøt L, Liedberg F, Höglund M.

Mod Pathol. 2018 Dec;31(12):1869-1881. doi: 10.1038/s41379-018-0096-5. Epub 2018 Jul 2.

PMID:
29967424
4.

Acute myeloid leukemia in very old patients.

Lazarevic VL, Bredberg A, Lorenz F, Ölander E, Antunovic P, Cammenga J, Wennström L, Möllgård L, Deneberg S, Derolf Å, Höglund M, Juliusson G.

Haematologica. 2018 Jun 28. pii: haematol.2018.196691. doi: 10.3324/haematol.2018.196691. [Epub ahead of print] No abstract available.

5.

Molecular subtype classification of urothelial carcinoma in Lynch syndrome.

Therkildsen C, Eriksson P, Höglund M, Jönsson M, Sjödahl G, Nilbert M, Liedberg F.

Mol Oncol. 2018 Aug;12(8):1286-1295. doi: 10.1002/1878-0261.12325. Epub 2018 Jun 19.

6.

Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients.

Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, Cornelissen JJ, Hoglund M, Westerweel PE.

Leukemia. 2018 Oct;32(10):2299-2303. doi: 10.1038/s41375-018-0136-7. Epub 2018 Apr 19. No abstract available.

PMID:
29743721
7.

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.

Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Lehn S, Sjölund J, Reid S, Larsson C, Eriksson P, Anderberg C, Cortez E, Saal LH, Orsmark-Pietras C, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K.

Nat Med. 2018 May;24(4):463-473. doi: 10.1038/nm.4494. Epub 2018 Mar 12.

8.

A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.

Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjödahl G, Höglund M.

Sci Rep. 2018 Feb 27;8(1):3737. doi: 10.1038/s41598-018-22126-x.

9.

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T.

Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.

10.

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson A, Chantzi E, Fryknäs M, Gullbo J, Nygren P, Gustafsson M, Höglund M, Larsson R.

Leuk Res. 2017 Dec;63:41-46. doi: 10.1016/j.leukres.2017.10.012. Epub 2017 Oct 28.

11.

Frequent miRNA-convergent fusion gene events in breast cancer.

Persson H, Søkilde R, Häkkinen J, Pirona AC, Vallon-Christersson J, Kvist A, Mertens F, Borg Å, Mitelman F, Höglund M, Rovira C.

Nat Commun. 2017 Oct 5;8(1):788. doi: 10.1038/s41467-017-01176-1.

12.

Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.

Jamalpour M, Li X, Cavelier L, Gustafsson K, Mostoslavsky G, Höglund M, Welsh M.

Tumour Biol. 2017 Oct;39(10):1010428317720643. doi: 10.1177/1010428317720643.

PMID:
28982308
13.

Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes.

Lindgren D, Eriksson P, Krawczyk K, Nilsson H, Hansson J, Veerla S, Sjölund J, Höglund M, Johansson ME, Axelson H.

Cell Rep. 2017 Aug 8;20(6):1476-1489. doi: 10.1016/j.celrep.2017.07.043.

14.

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlström H, Bill-Axelson A, Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T, Hellman P, Henriksson K, Hesselager G, Hultdin M, Häggman M, Höglund M, Jonsson H, Larsson C, Lindman H, Ljuslinder I, Mindus S, Nygren P, Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, Stålberg K, Stålberg P, Sundström C, Thellenberg Karlsson C, Westermark B, Bergh A, Claesson-Welsh L, Palmqvist R, Sjöblom T.

Acta Oncol. 2018 Feb;57(2):187-194. doi: 10.1080/0284186X.2017.1337926. Epub 2017 Jun 20.

PMID:
28631533
15.

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.

Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. No abstract available.

16.

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.

Eriksson P, Sjödahl G, Chebil G, Liedberg F, Höglund M.

Oncotarget. 2017 Jul 25;8(30):48905-48914. doi: 10.18632/oncotarget.16554.

17.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. Review.

18.

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.

Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf Å, Garelius H, Lazarevic V, Myhr-Eriksson K, Möllgård L, Uggla B, Wahlin A, Wennström L, Höglund M, Juliusson G.

Leukemia. 2017 Jun;31(6):1457-1459. doi: 10.1038/leu.2017.71. Epub 2017 Feb 24. No abstract available.

PMID:
28232742
19.

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.

Sjödahl G, Eriksson P, Liedberg F, Höglund M.

J Pathol. 2017 May;242(1):113-125. doi: 10.1002/path.4886. Epub 2017 Mar 28.

20.

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.

Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf ÅR, Deneberg S, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Lehmann S, Johansson B.

Eur J Haematol. 2017 May;98(5):493-500. doi: 10.1111/ejh.12861. Epub 2017 Mar 9.

PMID:
28152233
21.

The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.

Larfors G, Sandin F, Richter J, Själander A, Stenke L, Lambe M, Höglund M.

Eur J Haematol. 2017 Apr;98(4):398-406. doi: 10.1111/ejh.12845. Epub 2017 Jan 16.

PMID:
28009456
22.

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.

Strese S, Hassan SB, Velander E, Haglund C, Höglund M, Larsson R, Gullbo J.

Oncotarget. 2017 Jan 24;8(4):6341-6352. doi: 10.18632/oncotarget.13856.

23.

Reply to D. Pulte et al.

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM.

J Clin Oncol. 2017 Feb 20;35(6):696-697. doi: 10.1200/JCO.2016.70.9279. Epub 2016 Nov 28. No abstract available.

PMID:
27893321
24.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S.

Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28.

25.

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.

Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf Å, Garelius H, Lehmann S, Myhr-Eriksson K, Möllgård L, Uggla B, Wahlin A, Wennström L, Höglund M; Swedish AML Group and the Swedish Childhood Leukemia Group.

Leukemia. 2017 Mar;31(3):728-731. doi: 10.1038/leu.2016.312. Epub 2016 Oct 31. No abstract available.

26.

Utility of bronchoalveolar lavage in diagnosing respiratory tract infections in patients with hematological malignancies: are invasive diagnostics still needed?

Svensson T, Lundström KL, Höglund M, Cherif H.

Ups J Med Sci. 2017 Mar;122(1):56-60. doi: 10.1080/03009734.2016.1237595. Epub 2016 Oct 14.

27.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
28.

Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.

Österroos A, Kashif M, Haglund C, Blom K, Höglund M, Andersson C, Gustafsson MG, Eriksson A, Larsson R.

Biochem Pharmacol. 2016 Oct 15;118:40-49. doi: 10.1016/j.bcp.2016.08.020. Epub 2016 Aug 24.

PMID:
27565890
29.

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K.

Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.

PMID:
27499136
30.

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.

Söderlund S, Dahlén T, Sandin F, Olsson-Strömberg U, Creignou M, Dreimane A, Lübking A, Markevärn B, Själander A, Wadenvik H, Stenke L, Richter J, Höglund M.

Eur J Haematol. 2017 Jan;98(1):57-66. doi: 10.1111/ejh.12785. Epub 2016 Aug 19.

PMID:
27428357
31.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

32.

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM.

J Clin Oncol. 2016 Aug 20;34(24):2851-7. doi: 10.1200/JCO.2015.66.2866. Epub 2016 Jun 20.

PMID:
27325849
33.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

34.

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group.

Ann Intern Med. 2016 Aug 2;165(3):161-6. doi: 10.7326/M15-2306. Epub 2016 Jun 14.

PMID:
27295519
35.

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber FX, Stenke L, Eriksson KM, Markevärn B, Lübking A, Vestergaard H, Udby L, Bjerrum OW, Persson I, Mustjoki S, Olsson-Strömberg U.

Leukemia. 2016 Sep;30(9):1853-60. doi: 10.1038/leu.2016.121. Epub 2016 May 2.

PMID:
27133821
36.

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2016 Jul;30(7):1562-7. doi: 10.1038/leu.2016.59. Epub 2016 Mar 8.

PMID:
27080811
37.

[Put focus on bladder cancer].

Liedberg F, Höglund M.

Lakartidningen. 2016 Jan 6;113. pii: DUEE. Swedish. No abstract available.

38.

An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.

Holm K, Staaf J, Lauss M, Aine M, Lindgren D, Bendahl PO, Vallon-Christersson J, Barkardottir RB, Höglund M, Borg Å, Jönsson G, Ringnér M.

Breast Cancer Res. 2016 Feb 29;18(1):27. doi: 10.1186/s13058-016-0685-5.

39.

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

Gunnarsson N, Sandin F, Höglund M, Stenke L, Björkholm M, Lambe M, Olsson-Strömberg U, Richter J, Själander A.

Eur J Haematol. 2016 Oct;97(4):387-92. doi: 10.1111/ejh.12743. Epub 2016 Feb 26.

PMID:
26833713
40.

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Ntoufa S, Baliakas P, Clifford R, Sutton LA, Blakemore SJ, Stavroyianni N, Agathangelidis A, Rossi D, Höglund M, Kotaskova J, Juliusson G, Belessi C, Chiorazzi N, Panagiotidis P, Langerak AW, Smedby KE, Oscier D, Gaidano G, Schuh A, Davi F, Pott C, Strefford JC, Trentin L, Pospisilova S, Ghia P, Stamatopoulos K, Sjöblom T, Rosenquist R.

Blood. 2016 Feb 25;127(8):1007-16. doi: 10.1182/blood-2015-10-674572. Epub 2015 Dec 16.

41.

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.

Mosrati MA, Willander K, Falk IJ, Hermanson M, Höglund M, Stockelberg D, Wei Y, Lotfi K, Söderkvist P.

Oncotarget. 2015 Sep 22;6(28):25109-20. doi: 10.18632/oncotarget.4668.

42.

On Molecular Classification of Bladder Cancer: Out of One, Many.

Aine M, Eriksson P, Liedberg F, Höglund M, Sjödahl G.

Eur Urol. 2015 Dec;68(6):921-3. doi: 10.1016/j.eururo.2015.07.021. Epub 2015 Jul 26.

PMID:
26215606
43.

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.

Lazarevic V, Rosso A, Juliusson G, Antunovic P, Rangert-Derolf Å, Lehmann S, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Johansson B.

Am J Hematol. 2015 Sep;90(9):800-5. doi: 10.1002/ajh.24091. Epub 2015 Jul 22.

44.

Biological determinants of bladder cancer gene expression subtypes.

Aine M, Eriksson P, Liedberg F, Sjödahl G, Höglund M.

Sci Rep. 2015 Jun 8;5:10957. doi: 10.1038/srep10957.

45.

Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.

Eriksson P, Aine M, Veerla S, Liedberg F, Sjödahl G, Höglund M.

BMC Med Genomics. 2015 May 26;8:25. doi: 10.1186/s12920-015-0101-5.

46.

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia.

Eriksson A, Österroos A, Hassan S, Gullbo J, Rickardson L, Jarvius M, Nygren P, Fryknäs M, Höglund M, Larsson R.

Blood Cancer J. 2015 Apr 17;5:e307. doi: 10.1038/bcj.2015.31.

47.

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.

Gunnarsson N, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Richter J, Wadenvik H, Wallvik J, Själander A.

Br J Haematol. 2015 Jun;169(5):683-8. doi: 10.1111/bjh.13346. Epub 2015 Mar 27.

PMID:
25817799
48.

Epidemiology of chronic myeloid leukaemia: an update.

Höglund M, Sandin F, Simonsson B.

Ann Hematol. 2015 Apr;94 Suppl 2:S241-7. doi: 10.1007/s00277-015-2314-2. Epub 2015 Mar 27. Review.

PMID:
25814090
49.

Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma.

Aine M, Sjödahl G, Eriksson P, Veerla S, Lindgren D, Ringnér M, Höglund M.

Genome Med. 2015 Mar 10;7(1):23. doi: 10.1186/s13073-015-0144-4. eCollection 2015.

50.

A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S, Kollberg P, Eriksson P, Aine M, Månsson W, Fernö M, Liedberg F, Höglund M.

Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.

PMID:
25770486

Supplemental Content

Loading ...
Support Center